Novaccess Global Inc XSNX

Healthcare Biotechnology

NovAccess Global Inc. is a biopharmaceutical company, which develops immunotherapies to treat brain tumor patients in the United States. The Company specializes in research related to utilizing a patient’s own immune system to attack the cancer. Its dendritic cell-based immunotherapy utilizes a combination of Toll-like receptor adjuvants for an enhanced antitumor response. The therapy is designed to utilize the patient’s tumor antigens and immune cells, dendritic cells, in combination with TLR adjuvants to initiate an efficient antitumor immune response. This process includes obtaining the patients' tumor cells after surgery, and precursors cells that are matured into dendritic cells from peripheral blood. Its TLR-AD1 platform technology is a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. TLR-AD1 technology has a scope of use and is embodied in various different product lines for different clinical situations.

OTCPK:XSNX - Post by User

Novaccess Global Inc > Thank you - For Now

<< Previous

Bullboard Posts

Next >>

Post by Bullognaon Jan 03, 2018 1:18pm

201 Views

Post# 27271877

Thank you - For Now

To whomnever spammed this across the stock i was following - there is nothing wrong with taking a look at a stock being pumped to see if its right for you - for now this has been great, just wish i put more than pocket change into it. :) GLTA,

I have found many good stocks that was on someone elses suggestion

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market